Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
2.000
-0.150 (-6.98%)
Apr 22, 2026, 9:30 AM EST
Interpace Biosciences Revenue
In the year 2025, Interpace Biosciences had annual revenue of $38.73M, down -17.47%. Interpace Biosciences had revenue of $9.22M in the quarter ending December 31, 2025, a decrease of -25.68%.
Revenue
38.73M
Revenue Growth
-17.47%
P/S Ratio
1.43
Revenue / Employee
379.69K
Employees
102
Market Cap
55.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.73M | -8.20M | -17.47% |
| Dec 31, 2024 | 46.93M | 6.89M | 17.21% |
| Dec 31, 2023 | 40.04M | 8.20M | 25.75% |
| Dec 31, 2022 | 31.84M | -1.28M | -3.86% |
| Dec 31, 2021 | 33.12M | 719.00K | 2.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Global Cord Blood | 196.10M |
| Centogene | 53.65M |
| Bioqual | 46.54M |
| Psychemedics | 19.69M |
| Aspira Women's Health | 9.22M |
| ProPhase Labs | 4.90M |
| Longduoduo Company | 2.72M |
| IDenta | 1.34M |
Interpace Biosciences News
- 22 days ago - Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results - GlobeNewsWire
- 4 months ago - Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - GlobeNewsWire
- 5 months ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 7 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 1 year ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 1 year ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 1 year ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire